Just caught something interesting in the biotech space. Bioxytran announced their antiviral candidate ProLectin-M is moving forward with some solid dose optimization data. What caught my attention isn't just the clinical results, but how they're positioning this differently from what's already out there.

So here's the thing - most antivirals like Paxlovid work by blocking viral replication after infection takes hold. ProLectin-M takes a different angle using a galectin-blocking mechanism that basically stops the virus from entering cells in the first place. That's a meaningful distinction if it actually works as intended.

The data they released shows a 39-person study where the 16,800 mg/day dose hit 90% viral clearance by Day 5, which is pretty solid. More importantly, they're claiming better tolerability compared to earlier lower doses they tested. The safety profile looks favorable too, which matters for adoption.

Here's where it gets interesting for the regulatory path - they've been talking to both the FDA and India's CDSCO about moving into phase 3 trials. The planned phase 3 study is looking at around 408 participants in a randomized, placebo-controlled setup targeting standard-risk patients with mild-to-moderate COVID-19, influenza, and RSV. Primary endpoint is viral clearance or clinical improvement by Day 5 compared to placebo.

What's notable is they're positioning this as a potential first-line treatment rather than a backup option. If the phase 3 trial hits its marks, this could genuinely be the final step toward regulatory approval. The company is also exploring whether their galectin antagonist platform works beyond COVID, which suggests they see broader potential.

Stock-wise, BIXT has been trading between $0.03 and $0.2 over the past year. Closed Wednesday at $0.04, up 6.47%. Early stage biotech volatility, so typical for this space. Worth keeping on the radar if you follow antiviral development.